 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P3 trial: A Study in Chinese Patients With Acquired Blepharoptosis (clinicaltrials.gov) - Nov 12, 2024
P3, N=180, Recruiting, Sponsor: Santen Pharmaceutical Co., Ltd.
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial completion date, Trial primary completion date: Oxymetazoline Drops for Acquired Blepharoptosis from Synkinesis (clinicaltrials.gov) - Nov 12, 2024
P3, N=48, Enrolling by invitation, Sponsor: Milton S. Hershey Medical Center
Trial completion date: Jan 2025 --> Jul 2026 | Trial primary completion date: Oct 2024 --> Dec 2025
- |||||||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P3 trial: LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis. (clinicaltrials.gov) - Jul 22, 2024
P3, N=234, Not yet recruiting, Sponsor: Santen SAS
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment status: Oxymetazoline Drops for Acquired Blepharoptosis from Synkinesis (clinicaltrials.gov) - Mar 15, 2024
P3, N=48, Enrolling by invitation, Sponsor: Milton S. Hershey Medical Center
Trial completion date: Jan 2025 --> Jul 2026 | Trial primary completion date: Oct 2024 --> Dec 2025 Recruiting --> Enrolling by invitation
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment open: Oxymetazoline Drops for Acquired Blepharoptosis from Synkinesis (clinicaltrials.gov) - Feb 13, 2024
P3, N=48, Recruiting, Sponsor: Milton S. Hershey Medical Center
Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial initiation date: Oxymetazoline Drops for Acquired Blepharoptosis from Synkinesis (clinicaltrials.gov) - Sep 21, 2023
P3, N=48, Not yet recruiting, Sponsor: Milton S. Hershey Medical Center
Not yet recruiting --> Recruiting Initiation date: Aug 2023 --> Nov 2023
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P3 trial: Oxymetazoline Drops for Acquired Blepharoptosis from Synkinesis (clinicaltrials.gov) - Jul 14, 2023
P3, N=48, Not yet recruiting, Sponsor: Milton S. Hershey Medical Center
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial completion: The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance (clinicaltrials.gov) - Apr 24, 2023
P4, N=114, Completed, Sponsor: University of Miami
Initiation date: Aug 2023 --> Nov 2023 Active, not recruiting --> Completed
- || Upneeq (oxymetazoline hydrochloride) / Osmotica, Vuity (pilocarpine) / AbbVie
Looking forward to our 2022 #AntiAging #Eyecare #Innovations Day @VisionOptique @JNJVision #AcuvueMAX @abbvie #vuity #upneeq #EverTear @EyesaretheStory #ocularaesthetics #digitaleyehealth #digitaleyedoc https://t.co/uPkCdQWjqQ (Twitter) - Aug 3, 2022
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment closed: The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance (clinicaltrials.gov) - May 18, 2022
P4, N=114, Active, not recruiting, Sponsor: University of Miami
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Upneeq (oxymetazoline hydrochloride) / Osmotica
Clinical: $RVLP UPNEEQ® Wins Best Professional-Treatment Product by Shape Magazine in the 2022 "Shape Healthy Skin Awards" https://t.co/VtlM7HjsVc (Twitter) - May 9, 2022
- | Upneeq (oxymetazoline hydrochloride) / Osmotica
$OSMT RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022 https://t.co/IFjCrmlmH1 (Twitter) - Jan 18, 2022
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment open: The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance (clinicaltrials.gov) - Jun 24, 2021
P4, N=110, Recruiting, Sponsor: University of Miami
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Upneeq (oxymetazoline hydrochloride) / Osmotica
[VIRTUAL] Clinical responsiveness to RVL-1201, a novel oxymetazoline 0.1% ophthalmic solution for the treatment of acquired blepharoptosis: results from two phase 3 clinical studies () - May 13, 2021 - Abstract #ARVO2021ARVO_3830;
A large proportion of subjects demonstrated a positive response to once-daily RVL-1201 administration (superior visual field improvement). These results substantiate RVL-1201 as a potentially promising non-surgical treatment option for patients with acquired blepharoptosis.
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P4 trial: The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance (clinicaltrials.gov) - Apr 4, 2021
P4, N=110, Not yet recruiting, Sponsor: University of Miami
- Upneeq (oxymetazoline hydrochloride) / Osmotica
[VIRTUAL] PO298: Efficacy and Safety of RVL-1201 (Oxymetazoline 0.1%) for Acquired Blepharoptosis: Patient Subgroup Analysis from Two Phase 3 Studies () - Nov 11, 2020 - Abstract #AAO2020AAO_737;
Adverse event rates with RVL-1201 were comparable across subgroups, ranging from 24.3% to 38.5%. Conclusion RVL-1201 used once daily for 42 days had a consistent efficacy and safety profile across subgroups based on age or race.
- Upneeq (oxymetazoline hydrochloride) / Osmotica
[VIRTUAL] Industry Innovation Lunch sponsored by RVL Pharmaceuticals, Inc. - Managing Ptosis in Your Practice () - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_919;
Dr. Walter Whitley will review the mechanism of action and clinical data for RVL-1201, a new prescription eyedrop to treat acquired blepharoptosis in adults
- Upneeq (oxymetazoline hydrochloride) / Osmotica
[VIRTUAL] Safety Profile of a Novel Oxymetazoline Hydrochloride Ophthalmic Solution in Development for the Treatment of Acquired Blepharoptosis: Integrated Results from Four Clinical Studies (Track I - Academy at Home) - Oct 14, 2020 - Abstract #AAOPT2020AAOPT_433;
RVL-1201 was reported to cause “no discomfort” by 100%, 95.5%, and 92.0% of subjects using RVL-1201 once-daily for 2 weeks, 6 weeks, and 12 weeks, respectively. Conclusion The data from four double-masked, controlled clinical trials support the safety and tolerability of once-daily administration of RVL-1201 dosed up to 12 weeks. Taken together with previously reported efficacy data, these results support RVL-1201 as a potentially promising non-surgical treatment option for patients with acquired blepharoptosis.
- oxymetazoline hydrochloride (RVL-1201) / Osmotica
Preclinical examination of the toxicity and toxicokinetics of oxymetazoline HCl ophthalmic solution, 0.1% in rabbits (Exhibit Hall: Posterboard# B0027) - Mar 9, 2020 - Abstract #ARVO2020ARVO_3598;
Positive safety studies such as this in animals are a critical early step before advancing a drug to clinical studies in humans. Clinical studies of RVL-1201 have also been completed.
- ||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial completion: Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis (clinicaltrials.gov) - May 9, 2019
P3, N=164, Completed, Sponsor: RevitaLid Inc.
Clinical studies of RVL-1201 have also been completed. Recruiting --> Completed
- ||||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial completion: Study of Safety of RVL-1201 in Treatment of Blepharoptosis (clinicaltrials.gov) - Apr 4, 2019
P3, N=234, Completed, Sponsor: RevitaLid Inc.
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment closed: Study of Safety of RVL-1201 in Treatment of Blepharoptosis (clinicaltrials.gov) - Jan 14, 2019
P3, N=225, Active, not recruiting, Sponsor: RevitaLid Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P3 trial: Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis (clinicaltrials.gov) - Jul 15, 2018
P3, N=156, Recruiting, Sponsor: RevitaLid Inc.
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment open: Study of Safety of RVL-1201 in Treatment of Blepharoptosis (clinicaltrials.gov) - Jul 11, 2018
P3, N=225, Recruiting, Sponsor: RevitaLid Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment open: Study of Safety and Efficacy of RVL-1201 in the Treatment of Blepharoptosis (clinicaltrials.gov) - Jul 10, 2018
P3, N=156, Recruiting, Sponsor: RevitaLid Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P3 trial: Study of Safety of RVL-1201 in Treatment of Blepharoptosis (clinicaltrials.gov) - Jun 3, 2018
P3, N=225, Not yet recruiting, Sponsor: RevitaLid Inc.
- ||||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial completion: Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis (clinicaltrials.gov) - Dec 7, 2016
P3, N=139, Completed, Sponsor: RevitaLid Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment closed, Trial primary completion date: Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis (clinicaltrials.gov) - Oct 26, 2016
P3, N=139, Active, not recruiting, Sponsor: RevitaLid Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
- |||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial primary completion date: Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis (clinicaltrials.gov) - Mar 2, 2016
P3, N=150, Recruiting, Sponsor: RevitaLid Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2016 Trial primary completion date: Mar 2016 --> Jun 2016
- |||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment open: Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis (clinicaltrials.gov) - Jan 15, 2016
P3, N=150, Recruiting, Sponsor: RevitaLid Inc.
Trial primary completion date: Mar 2016 --> Jun 2016 Not yet recruiting --> Recruiting
- |||||||||| Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P3 trial: Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis (clinicaltrials.gov) - May 7, 2015
P3, N=150, Not yet recruiting, Sponsor: RevitaLid Inc.
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Enrollment change: Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis (clinicaltrials.gov) - Feb 3, 2014
P1/2, N=46, Completed, Sponsor: RevitaLid Inc.
Not yet recruiting --> Recruiting N=72 --> 46
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
Trial completion: Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis (clinicaltrials.gov) - Feb 3, 2014
P1/2, N=46, Completed, Sponsor: RevitaLid Inc.
N=72 --> 46 Recruiting --> Completed
- | Upneeq (oxymetazoline hydrochloride) / RVL Pharma
New P1/2 trial: Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis (clinicaltrials.gov) - May 5, 2013
P1/2, N=46, Completed, Sponsor: RevitaLid Inc.